资源描述
,Click to edit Master title style,Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,社区获得性肺炎,308,、,313,研究组,泰阁,替加环素与亚胺培南,/,西司他丁,治疗,院内获得性肺炎,对照研究,311,研究,311,研究背景与目的,背景,:,院内获得性肺炎,(HAP),具有较高的发病率及死亡率,HAP,归因死亡率高达,33%-50%,之间,延迟治疗使,HAP,患者死亡率增加,60%,ATS,制订,HAP,指南,旨在提高,HAP,诊治水平,挽救更多患者生命,目的:,比较替加环素与亚胺培南,/,西司他丁治疗,HAP,患者的疗效和安全,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,311,研究,研究方法,对,2004,年,3,月至,2006,年,12,月,31,个国家,138,个研究机构的,945,例,HAP,患者进行的,III,期、随机、对照、双盲,(,第三方非盲,),研究,患者随机分为两组,分别使用替加环素和亚胺培南,/,西司他丁治疗,7-14,天,替加环素组:初始,100mg iv,,随后,50mg iv,bid;,考虑铜绿假单胞菌感染时,加用头孢他啶,2g iv tid,亚胺培南,/,西司他丁组:,500 mg-,1g iv tid,;考虑,MRSA,感染时,加用万古霉素,1g iv,bid,为了对试验治疗,(TOC),进行评估,必须在研究药物末次给药后,10-21,天内进行评价,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,患者入选标准,年龄,18,岁,入院,48,小时后出现症状或症状消除小于,7,天,(,初次入院者应大于,3,天,),X,线显示新发或有进展的浸润影,至少存在发热、或伴随需要使用机械通气的呼吸衰竭时的白细胞增多,/,白细胞减少,或至少符合下列情况中的,2,种,咳嗽,呼吸困难或呼吸急促,胸膜炎所致胸痛,听诊有罗音和,/,或肺组织实变迹象,低氧血症,脓痰或痰液性状有所改变,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,患者排除标准,疑似,HAP,时使用抗菌药物治疗超过,24,小时,除外呼吸道培养显示致病菌对药物耐药或患者病情加重,HIV,阳性,接受免疫抑制治疗,APACHE II,评分,30,胆囊纤维化,肺恶性肿瘤,支气管扩张,伯克氏肉样瘤,肺脓肿,脓胸,活动期结核,明确由军团菌、肺囊虫引起的感染,其它附加条件:,中性粒细胞绝对计数,1 10,9,/L,天冬氨酸转氨酶或丙氨酸转氨酶超过正常上限的,10,倍,胆红素或碱性磷酸酶超过正常上限的,3,倍,肌酐清除率,15,分,,n(%),110(23.6),58(21.6),118(25.3),57(23.5),15,分,,n(%),357(76.4),210(78.4),349(74.7),186(76.5),CrCl(mL/min),98.8,109.9,104.7,138.5,98.8,49.0,99.3,51.1,诊断,0.508,0.933,VAP,n(%),131(28.1),73(27.2),122(26.1),67(27.6),非,VAP,,,n(%),336(71.9),195(72.8),345(73.9),176(72.4),311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,入选患者基线临床特征,特征,替加环素,亚胺培南,/,西司他丁,P,mITT,(n=467),CE,(n=268),mITT,(n=467),CE,(n=243),mITT,CE,既往使用抗菌药物,,n(%),138(29.6),67(25.0),139(29.8),53(21.8),0.943,0.396,多叶性病变,,n(%),250(54.6),145(54.1),243(52.6),130(53.5),0.533,0.929,双叶浸润,,n(%),198(43.2),112(41.8),204(44.2),114(46.9),0.791,0.248,胸腔积液,,n(%),152(33.0),85(31.7),132(28.4),66(27.2),0.135,0.286,早发,HAP5,天,54(20.0),43(17.7),晚发,HAP5,天,214(80.0),200(82.3),获得性感染,,n(%),0.383,0.924,长期护理设施,22(4.7),16(6.0),28(6.0),15(6.2),住院,445(95.3),252(94.0),439(94.0),228(93.8),ME,患者,替加环素,(n=194),亚胺培南,/,西司他丁,(n=189),菌血症,28(14.4),31(16.4),311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,研究结果,311,研究,治疗,HAP,的临床疗效,临床治愈率,(%),CE,人群,c-mITT,人群,P=0.12,P=0.001,182/268,190/243,53/243,86/268,276/440,290/429,122/440,91/429,42/440,48/429,95%CI,,,-17.8-3.0,95%CI,,,-11.01.3,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),治疗,VAP,、非,VAP,临床疗效,(1),临床治愈率,(%),CE,人群:,VAP,CE,人群:非,VAP,95%CI:,-22.2(-37.8 to-4.9),95%CI:,-5.9(-14.5 to 3.0),35/73,38/73,33/176,147/195,143/176,20/67,47/67,48/195,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),治疗,VAP,、非,VAP,临床疗效,(2),临床治愈率,(%),c-mITT,人群:,VAP,c-mITT,人群:非,VAP,95%CI:,-11.3(-24.6 to 2.0),95%CI:,-1.9(-9.4 to 5.6),311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),对不同致病菌所致非,VAP,的临床疗效,致病菌,替加环素治愈率,n/N(%),亚胺培南,/,西司他丁治愈率,n/N(%),MSSA,29/36(80.6),36/39(92.3),MRSA,8/17(47.1),14/19(73.7),流感嗜血杆菌,8/11(72.7),2/2(100.0),肺炎克雷伯菌,19/25(76.0),18/22(81.8),鲍曼不动杆菌,9/10(90.0),12/17(70.6),大肠埃希菌,19/22(86.4),19/22(86.4),嗜麦芽窄食单胞菌,1/1(100.0),1/1(100.0),阴沟肠杆菌,8/10(80.0),7/7(100.0),铜绿假单胞菌,7/11(63.6),9/13(69.2),沙雷氏菌属,3/7(75.0),1/2(,50.0),非,PI/PRSP,10/10(100.0),4/4(100.0),PISP,1/1(100.0),PRSP,1/2(50.0),0/1(0),PISP,:青霉素中度耐药肺炎链球菌。,PI,:青霉素中度耐药。,PRSP,:青霉素耐药肺炎链球菌。,MSSA,:甲氧西林敏感金黄色葡萄球菌;,MRSA,:耐甲氧西林金黄色葡萄球菌,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),对不同致病菌所致,VAP,的临床疗效,致病菌,替加环素治愈率,n/N(%),亚胺培南,/,西司他丁治愈率,n/N(%),MSSA,5/9(55.6),11/16(68.8),MRSA,4/10(40.0),9/11(81.8),流感嗜血杆菌,2/4(50.0),4/4(100.0),肺炎克雷伯菌,1/5(20.0),5/5(100.0),鲍曼不动杆菌,12/21(57.1),18/19(94.7),大肠埃希菌,1/4(25.0),4/6(66.7),嗜麦芽窄食单胞菌,2/2(100.0),2/4(50.0),阴沟肠杆菌,2/2(100.0),0/1(0),铜绿假单胞菌,3/11(27.3),6/7(85.7),沙雷氏菌属,0/2(0),1/2(50.0),非,PI/PRSP,2/2(100.0),1/1(100.0),PISP,1/1(100.0),1/1(100.0),PISP,:青霉素中度耐药肺炎链球菌。,PI,:青霉素中度耐药。,PRSP,:青霉素耐药肺炎链球菌。,MSSA,:甲氧西林敏感金黄色葡萄球菌;,MRSA,:耐甲氧西林金黄色葡萄球菌,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),对,HAP,常见致病菌的体外抗菌活性,致病菌,n,替加环素,MIC,范围,mg/mL,替加环素,MIC,50,mg/mL,替加环素,MIC,90,mg/mL,TOC,时治愈率,n/N(%),TOC,时清除率,n/N(%),鲍曼不动杆菌,67,0.12-8.00,1.00,4.00,21/31(67.7),22/31(71.0),大肠埃希菌,54,0.12-2.00,0.25,0.50,20/26(76.9),20/26(76.9),阴沟肠杆菌,20,0.25-2.00,0.50,1.00,10/12(83.3),12/12(100.0),流感嗜血杆菌,21,0.06-0.50,0.25,0.50,10/15(66.7),12/15(80.0),肺炎克雷伯菌,57,0.06-4.00,0.50,2.00,20/30(66.7),22/30(73.3),铜绿假单胞菌,42,8.00-64.00,16.00,32.00,10/22(45.5),11/22(50.0),MSSA,100,0.06-0.50,0.12,0.25,34/45(75.6),37/45(82.2),MRSA,57,0.06-2.00,0.25,0.50,12/27(44.4),12/27(44.4),嗜麦芽窄食单胞菌,8,0.25-0.50,NA,NA,3/3(100.0),2/3(66.7),沙雷氏菌属,10,1.00-2.00,1.00,2.00,3/6(50.0),3/6(50.0),非,PI/PRSP,17,0.03-0.12,0.06,0.12,12/12(100.0),12/12(100.0),PISP,3,0.03-0.12,NA,NA,1/1(100.0),1/1(100.0),PRSP,3,0.06-0.06,NA,NA,1/2(50.0),1/2(50.0),311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,泰阁,(,替加环素,),治疗的安全性,药物相关不良事件,替加环素,n=467,亚胺培南,/,西司他丁,n=467,P,任何不良事件,368(78.8),367(78.6),1.000,恶心,72(15.4),37(7.9),0.001,呕吐,59(12.6),34(7.3),0.008,腹泻,49(10.5),70(15.0),0.049,白细胞增多,47(10.1),42(9.0),0.656,贫血,32(6.9),45(9.6),0.153,低血压,30(6.4),36(7.7),0.523,血小板增多,29(6.2),33(7.1),0.694,发热,28(6.0),39(8.4),0.205,高血压,27(5.8),29(6.2),0.981,感染,26(5.6),26(5.6),1.000,末梢浮肿,25(5.4),18(3.9),0.349,皮肤溃疡,25(5.4),10(2.1),0.015,低蛋白血症,24(5.1),16(3.4),0.258,低血钾,24(5.1),33(7.1),0.274,胸膜渗液,22(4.7),24(5.1),0.880,311,研究,1,、,Freire AT et al.Diagnostic Microbiology and Infectious Disease.2010;68:140-151.,思考题,请阐述,311,研究的研究设计、入选人群、对照组药物、试验结果?,随机双盲对照试验,HAP,患者,与亚胺培南对照,两者临床疗效相当,
展开阅读全文